NYSEAMERICAN:PFNX - Pfenex Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pfenex Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.62 -0.24 (-2.21 %) (As of 12/5/2019 04:00 PM ET) Add Compare Today's Range$10.51Now: $10.62▼$10.8750-Day Range N/A52-Week Range$3.13Now: $10.62▼$11.39Volume181,600 shsAverage Volume210,931 shsMarket Capitalization$336.40 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. Read More… Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PFNX Previous SymbolNYSEMKT:PFNX CUSIPN/A CIKN/A Webhttp://www.pfenex.com/ Phone+1-858-3524400Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees71 Outstanding Shares31,676,000Market Cap$336.40 million Next Earnings Date3/9/2020 (Estimated) OptionableOptionable Receive PFNX News and Ratings via Email Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter. AMEX:PFNX Rates by TradingView Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions What is Pfenex's stock symbol? Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX." How were Pfenex's earnings last quarter? Pfenex Inc (NYSEAMERICAN:PFNX) posted its earnings results on Thursday, November, 7th. The biotechnology company reported $0.09 earnings per share for the quarter, meeting analysts' consensus estimates of $0.09. The biotechnology company earned $15.25 million during the quarter, compared to analysts' expectations of $14.80 million. View Pfenex's Earnings History. When is Pfenex's next earnings date? Pfenex is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Pfenex. What price target have analysts set for PFNX? 4 equities research analysts have issued 1 year price targets for Pfenex's stock. Their forecasts range from $17.00 to $20.00. On average, they expect Pfenex's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 74.2% from the stock's current price. View Analyst Price Targets for Pfenex. What is the consensus analysts' recommendation for Pfenex? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex. Has Pfenex been receiving favorable news coverage? News coverage about PFNX stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfenex earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Pfenex. Are investors shorting Pfenex? Pfenex saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 890,400 shares, an increase of 68.3% from the September 15th total of 529,100 shares. Based on an average daily trading volume, of 320,500 shares, the short-interest ratio is currently 2.8 days. Currently, 2.8% of the company's stock are short sold. View Pfenex's Current Options Chain. Who are some of Pfenex's key competitors? Some companies that are related to Pfenex include Concordia International (CXR), Polynovo (PNV), Kodiak Sciences (KOD), Immutep (IMM), Mesoblast (MSB), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Oxford BioMedica (OXB), Starpharma (SPL), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Biotest (BIO), Bellus Health (BLU), Neptune Wellness Solutions (NEPT) and ProMetic Life Sciences (PLI). What other stocks do shareholders of Pfenex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Ocular Therapeutix (OCUL), Fate Therapeutics (FATE), Opko Health (OPK), Relypsa (RLYP), Spectrum Pharmaceuticals (SPPI), TherapeuticsMD (TXMD), Verastem (VSTM), Alder Biopharmaceuticals (ALDR), Coherus Biosciences (CHRS) and Dicerna Pharmaceuticals (DRNA). Who are Pfenex's key executives? Pfenex's management team includes the folowing people: Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)Dr. Hubert C. Chen, Advisor (Age 50)Ms. Susan A. Knudson, Chief Financial Officer (Age 55) Who are Pfenex's major shareholders? Pfenex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.74%), Millennium Management LLC (0.82%), Squarepoint Ops LLC (0.55%), Russell Investments Group Ltd. (0.48%), Commonwealth Equity Services LLC (0.25%) and Point72 Asset Management L.P. (0.24%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex. Which major investors are selling Pfenex stock? PFNX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Man Group plc, Zurcher Kantonalbank Zurich Cantonalbank, Commonwealth Equity Services LLC and Barclays PLC. View Insider Buying and Selling for Pfenex. Which major investors are buying Pfenex stock? PFNX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Point72 Asset Management L.P., State Street Corp, Delta Investment Management LLC, Metropolitan Life Insurance Co NY, California Public Employees Retirement System and California State Teachers Retirement System. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex. How do I buy shares of Pfenex? Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Pfenex's stock price today? One share of PFNX stock can currently be purchased for approximately $10.62. How big of a company is Pfenex? Pfenex has a market capitalization of $336.40 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex. What is Pfenex's official website? The official website for Pfenex is http://www.pfenex.com/. How can I contact Pfenex? Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400. MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 186 (Vote Underperform)Total Votes: 375MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/5/2019 by MarketBeat.com StaffFeatured Article: Capital Gains Distribution